ELSA (EarLy Surveillance for Autoimmune diabetes)

ELSA (EarLy Surveillance for Autoimmune diabetes) is a UK research programme, led from the University of Birmingham and co-funded by Diabetes UK and Breakthrough T1D, that tests whether screening the general childhood population for type 1 diabetes (T1D) is feasible and acceptable enough to become a national NHS service.¹ It is not a treatment — it is the front door to early detection.

What is screened, and the staging model

The immune attack behind T1D produces islet autoantibodies that appear in the blood 10-15 years before any symptom; finding two or more means future insulin-requiring T1D is almost certain.¹ ELSA measures these with a finger-prick dried blood spot that families can do at home, at school, at the GP or in hospital, then post back — far less burdensome than a clinic blood draw.¹ A positive screen is confirmed by a venous test, and children with two or more autoantibodies have an oral glucose tolerance test to stage the disease: Stage 1 (autoantibodies, normal glucose), Stage 2 (autoantibodies plus dysglycaemia), and Stage 3 (clinical diabetes) — a staging framework now embedded in international guidelines and diagnostic codes.¹

Who, predictive value and reach

ELSA screens children and young people aged 2-17 across England, Scotland, Wales and Northern Ireland, deliberately recruiting in deprived and underserved communities — because most new T1D occurs in people with no family history, which family-only screening misses.²³ The original protocol set out to screen 20,000 children aged 3-13 and was statistically powered to find about 60 (0.3%) with early-stage T1D, an autoantibody prevalence anchored to Germany's Fr1da study, which found presymptomatic T1D in 0.31% of 90,632 children.¹⁴ The assay ELSA validated on dried blood spots is 89% sensitive and 100% specific.¹

What early detection enables (and the DKA case)

The biggest immediate prize is avoiding diabetic ketoacidosis (DKA) — the dangerous, sometimes fatal crisis in which over a quarter of UK children are still diagnosed.³ Screening programmes abroad have cut DKA at onset from as high as 40% to under 5%.⁴ Children ELSA finds early arrive in much gentler shape — one case series reported a median HbA1c of 6.6% and low insulin needs — though a few progressed quickly, underlining why symptom education accompanies every result.⁵ Early knowledge also gives families time to prepare and unlocks access to monitoring and prevention trials.¹

Safety, cost and acceptability

Risks are modest: the finger-prick is low-pain, only the 1-2% who screen positive need invasive follow-up, and a real concern — parental anxiety after a positive result — was shown to fade within 12 months in earlier studies, with counselling and psychology support built into ELSA.¹ The honest limitation is access: ELSA is a time-limited study, not yet a funded national programme, and its feasibility and cost-effectiveness findings are designed to inform that decision.⁶

What's coming

In 2026, ELSA's team reported the feasibility results of UK general-population screening, providing what commentators called a "blueprint" for a national programme.⁷ The case for screening is strengthened by teplizumab, the first therapy shown to delay T1D — by a median of roughly two to three years in at-risk people (59.6 vs 27.1 months in the TN-10 trial) — licensed by the MHRA in the UK (age 8+),⁸ FDA-approved since 2022, and now recommended by NICE for NHS use in stage 2 T1D: final draft guidance on 23 June 2026, confirmed in final guidance (TA1176) on 9 July 2026, making England the first country in Europe to recommend it through a health technology appraisal.⁹¹⁰¹¹ The guidance covers NHS England and Wales (not Scotland or Northern Ireland); NHS Wales has 60 days from 23 June 2026 to make it available, NHS England 90 days from publication of the final guidance. NICE estimates about 1,100 eligible people in England and Wales in the first year, settling to roughly 820 a year from year three.¹⁰

That is where ELSA becomes the bottleneck. NICE says people are likely to learn they have stage 2 T1D in one of only three ways: by taking part in a research study — ELSA in children aged 2-17, T1DRA in adults aged 18-70 — by being tested because a family member has T1D, or by being tested for some other medical reason.¹⁰ With no screening programme, the therapy has few people to reach: screening is the rate-limiting step for the drug rather than the other way round. ELSA also feeds the European EDENT1FI consortium working toward early T1D detection across countries.¹

The decision that is actually pending

A feasibility result is not a programme. Whether the UK screens children for T1D is a policy decision — screening programmes are recommended to ministers by the UK National Screening Committee, and no such recommendation for general-population childhood T1D screening exists today. ELSA's feasibility and cost-effectiveness findings are explicitly designed to inform that decision.⁶

There is real political pressure, but it has not yet changed anything. MPs debated infant testing for type 1 diabetes in Westminster Hall on 9 March 2026, prompted by a public petition that gathered over 120,000 signatures following the death of two-year-old Lyla Story in May 2025.¹² A Type 1 Diabetes Screening (Children) Bill was subsequently introduced in the Commons by Sarah Bool MP under the ten-minute rule.¹³ It has had a first reading only; bills introduced this way rarely proceed without government support. Treat all of this as momentum, not as a decision — the screening pathway a family can actually use today is still a research study, not an NHS service.

References

1. Quinn LM, et al. Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening — the EarLy Surveillance for Autoimmune diabetes (ELSA) study. Diabetic Medicine (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006551/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

2. The ELSA Study (official site), University of Birmingham / NHS. elsadiabetes.nhs.uk (accessed 2026). https://www.elsadiabetes.nhs.uk/ ↩

3. Diabetes UK. Screening children for type 1 diabetes: The ELSA study. diabetes.org.uk (accessed 2026). https://www.diabetes.org.uk/our-research/about-our-research/our-funded-projects/midlands/type-1-diabetes-screening-elsa ↩ ↩²

4. Ziegler AG, et al. Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany (Fr1da). JAMA (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990943/ ↩ ↩²

5. Quinn LM, et al. Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study. BMJ Open Diabetes Research & Care (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11429353/ ↩

6. Quinn LM, et al. EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1). BMJ Open Diabetes Research & Care (2022). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024254/ ↩ ↩²

7. Quinn LM, et al. Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study. The Lancet Diabetes & Endocrinology (2026). https://pubmed.ncbi.nlm.nih.gov/41576975/ ↩

8. Diabetes UK. Groundbreaking immunotherapy drug teplizumab licensed in UK for delaying early stages of type 1 diabetes. diabetes.org.uk (2024). https://www.diabetes.org.uk/about-us/news-and-views/groundbreaking-immunotherapy-drug-teplizumab-licensed-uk-delaying-early ↩

9. Herold KC, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (TN-10). New England Journal of Medicine (2019). https://pubmed.ncbi.nlm.nih.gov/31180194/ ↩

10. NICE. First disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommended. nice.org.uk (23 June 2026). https://www.nice.org.uk/news/articles/teplizumab-to-delay-the-onset-of-type-1-diabetes-recommended ↩ ↩² ↩³

11. NICE. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes. Technology appraisal guidance TA1176 (9 July 2026). https://www.nice.org.uk/guidance/ta1176 ↩

12. Type 1 Diabetes: Infant Testing. Hansard, House of Commons (9 March 2026). https://hansard.parliament.uk/Commons/2026-03-09/debates/140525A1-26CC-48A6-8FB9-E2E91CB67807/Type1DiabetesInfantTesting ↩

13. Type 1 Diabetes Screening (Children) Bill. UK Parliament (2026). https://bills.parliament.uk/bills/4109 ↩